Extent of polymorphism and selection pressure on the Trypanosoma cruzi vaccine candidate antigen Tc24. (10th September 2020)

• Record Type: Journal Article
• Authors: Arnal, Audrey; Villanueva‐Lizama, Liliana; Teh‐Poot, Christian; Herrera, Claudia; Dumonteil, Eric
• Is Part Of: Evolutionary applications. Volume 13:Number 10(2020)
• Page Start: 2663
• Page End: 2672
• Publication Date: 2020-09-10
• Subjects: antigenic variation -- calcium‐binding -- Chagas disease -- kinetoplastid -- vaccine; Evolution (Biology) -- Periodicals; Genetics -- Periodicals; Natural selection -- Periodicals; Ecology -- Periodicals; 576.8
• DOI: 10.1111/eva.13068
• Languages: English
• ISSNs: 1752-4571

Abstract

Abstract: Introduction: Chagas disease, caused by the protozoan parasite Trypanosoma cruzi, is a major public health problem in the Americas, and existing drugs have severe limitations. In this context, a vaccine would be an attractive alternative for disease control. One of the difficulties in developing an effective vaccine lies in the high genetic diversity of T. cruzi . In this study, we evaluated the level of sequence diversity of the leading vaccine candidate Tc24 in multiple parasite strains. Methods and Results: We quantified its level of polymorphism within and between T. cruzi discrete typing units (DTUs) and how this potential polymorphism is structured by different selective pressures. We observed a low level of polymorphism of Tc24 protein, weakly associated with parasite DTUs, but not with the geographic origin of the strains. In particular, Tc24 was under strong purifying selection pressure and predicted CD8 + T‐cell epitopes were mostly conserved. Tc24 strong conservation may be associated with structural/functional constrains to preserve EF hand domains and their calcium‐binding loops, and Tc24 is likely important for the parasite fitness. Discussion: Together, these results show that a vaccine based on Tc24 is likely to be effective against a wide diversity of parasite strains across the American continent, and further development of this vaccine candidate should be a high priority.